What is a "mini-tender" offer mentioned in the filing?

A mini-tender offer is a type of unsolicited offer made by a third party (not the company itself) to purchase a small number of a company's outstanding shares at a price that is typically below the current market value. These offers can sometimes be confusing for investors and may have hidden fees or unfavorable terms.

Why is Bristol-Myers Squibb issuing this warning?

Bristol-Myers Squibb is issuing this warning to protect its shareholders. The company does not endorse Tutanota's offer and believes it may not be in the best interest of shareholders, likely because the offer price is significantly lower than the market value of the stock and could be subject to unfavorable conditions.

Should I tender my shares to Tutanota at $55.00 per share?

Bristol-Myers Squibb's official recommendation is NOT to tender your shares. The company advises shareholders against accepting this unsolicited offer, suggesting that $55.00 per share is likely a disadvantageous price compared to the stock's market value. Investors should review the current market price of BMY stock before making any decisions.

What should I do if I already tendered my shares?

If you have already tendered your shares, you have the right to withdraw them prior to the offer's expiration. The offer is scheduled to expire on February 23, 2024, unless extended or terminated. You should consult Tutanota's offering documents for the specific withdrawal procedures.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report primarily to address an unsolicited "mini-tender" offer from Tutanota LLC. Tutanota is attempting to purchase a small percentage of BMY's outstanding shares (less than 0.025%) at a price of $55.00 per share. The company explicitly states it does not endorse this offer and advises its shareholders not to tender their shares. This action is a protective measure for shareholders, aiming to prevent them from accepting an offer that is likely significantly below the market value of BMY stock and potentially subject to unfavorable terms. Investors should be aware that this 8-K filing is a cautionary announcement, not an indication of significant company performance or strategic shifts. The unsolicited offer is from a third party and is not associated with Bristol-Myers Squibb. The company's recommendation against tendering shares suggests that shareholders who accept this offer may be selling their stock at a discount. Shareholders who have already tendered are advised to consider withdrawing their shares before the offer's expiration on February 23, 2024.

Key Highlights

1BMY is warning shareholders about an unsolicited "mini-tender" offer from Tutanota LLC.
2The offer is to purchase a very small fraction of outstanding shares (less than 0.025%).
3The offer price is $55.00 per share.
4Bristol-Myers Squibb does not endorse the offer and recommends shareholders NOT tender their shares.
5The company is not affiliated with Tutanota or its offer.
6Shareholders who have tendered can withdraw their shares before the offer expires on February 23, 2024.
7This filing is a cautionary alert to protect shareholders from potentially disadvantageous offers.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 14, 2024)

Summary

Key Highlights

Frequently Asked Questions